drugset / Trial / NCT07174583
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.
Timeline
- Start
- 2025-10-14
- Primary completion
- 2029-07
- Completion
- 2029-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Durvalumab | Monoclonal antibody | — | Intravenous |
| Subject | IDE161 | Unknown | — | Oral |
| Subject | IDE849 | Unknown | — | Intravenous |